Navigation Links
U.S. Food and Drug Administration (FDA) Delays Review of Takeda's Investigational Type 2 Diabetes Therapies, Alogliptin and Alogliptin/Pioglitazone
Date:11/18/2011

DEERFIELD, Ill., and OSAKA, Japan, Nov. 18, 2011 /PRNewswire/ -- Takeda Pharmaceutical Company Limited (Takeda) and its wholly-owned subsidiary, Takeda Global Research & Development Center, Inc., U.S., today announced that the company received notification from the U.S. Food and Drug Administration (FDA) that its review of investigational type 2 diabetes therapy alogliptin, and thus the fixed-dose combination therapy alogliptin/pioglitazone, will be delayed. The new Prescription Drug User Fee Act (PDUFA) action date has been set for April 25, 2012. The FDA originally assigned a PDUFA action date of January 25, 2012.

"Takeda is confident in alogliptin and alogliptin/pioglitazone as potential therapeutic options for the millions of patients living with type 2 diabetes," said David Recker, M.D., senior vice president, clinical science, Takeda Global Research & Development Center, Inc., U.S. "We will work closely with the FDA to determine the appropriate next steps, and are dedicated to continuing our efforts to bring these important therapies to market in the U.S."

Alogliptin is a highly potent and highly selective dipeptidyl peptidase IV inhibitor (DPP-4i) under investigation in the U.S. for the treatment of type 2 diabetes as an adjunct to diet and exercise. Discovered by Takeda San Diego, Inc., alogliptin is designed to slow the inactivation of incretin hormones GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic peptide), which play roles in regulating blood glucose levels. Alogliptin/pioglitazone combines alogliptin with pioglitazone, two complementary agents with distinct mechanisms of action, and if approved, will be the first type 2 diabetes treatment option in the U.S. to include both a DPP-4 inhibitor and a thiazolidinedione (TZD) in a single tablet. Pioglitazone was approved in 1999 for the treatment of type 2 diabetes as an adjunct to diet and exercise.

There is no change in Takeda's fiscal 2011 financ
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration
2. Supplemental New Drug Application for PREZISTA(TM) Submitted to U.S. Food and Drug Administration
3. Northwestern Offers Clinical Research and Regulatory Administration Graduate Certificate Program
4. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
5. Ortho Biotech Statement on U.S. Food and Drug Administration Oncologic Drugs Advisory Committee Vote
6. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
7. Treprostinil Data Presented at American Thoracic Society Conference Demonstrates Significant Clinical Progress in All Four Routes of Administration
8. Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
9. Genmab A/S - Company Announcement Ofatumumab in Subcutaneous Study in Rheumatoid Arthritis Summary: Subcutaneous Administration of Ofatumumab Investigated in Phase I/II Study
10. Vermillion Files 510(k) Application With U.S. Food & Drug Administration for OVA1 Ovarian Tumor Triage Test
11. New Drug Application for Inhaled Treprostinil Submitted to the U.S. Food and Drug Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 29, 2014  Pacific Medical Data Solutions is excited ... design . The main website, along with the site,s ... new services and content relevant to the medical billing ... design, viewers can now better understand how PMDS products ... and create a more visible platform about medical billing ...
(Date:8/29/2014)... Research and Markets  has announced the ... Devices Market 2014-2018" report to their offering. ... cells that connect, support, or surround bones. There are ... ligaments, cartilage, fascia, and other fibrous tissues. Repetitive use, ... age result in wear and tear in these tissues. ...
(Date:8/28/2014)... NEW YORK, Aug. 28, 2014 Reportlinker.com ... available in its catalogue: North America ... 2020 http://www.reportlinker.com/p02343466/North-America-Aesthetic-Lasers-and-Energy-Devices-Market-Outlook-to-2020.html ... Market Outlook to 2020 Summary GlobalData,s ... Devices Market Outlook to 2020", provides key market ...
Breaking Medicine Technology:PMDS Announces New Website 2Global Orthopedic Soft Tissue Repair Devices Market 2014-2018: Key Vendors are ArthroCare, Biomet, DePuy Synthes and Smith & Nephew 2Global Orthopedic Soft Tissue Repair Devices Market 2014-2018: Key Vendors are ArthroCare, Biomet, DePuy Synthes and Smith & Nephew 3North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 2North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 3North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 4North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 5North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 6North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 7North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 8North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 9North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 10North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 11North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 12North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 13North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 14North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 15North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 16
... Hereditary hearing loss is the most common sensory disorder in ... the Institute of Human Genetics at the ... methods, including Roche,s NimbleGen Custom Sequence Capture 385K array to ... X-chromosome of a Spanish family with hereditary hearing loss (1). ...
... Inc. announced today that the first patient has been ... an oligoclonal therapeutic consisting of a mixture of three ... epitopes of the epidermal growth factor receptor (EGFR). ... safety of MM-151 and determine the recommended Phase 2 ...
Cached Medicine Technology:Roche's Sequence Capture Technology Used to Identify SMPX Mutations Underlying Human Hereditary Hearing Loss 2Roche's Sequence Capture Technology Used to Identify SMPX Mutations Underlying Human Hereditary Hearing Loss 3
(Date:8/29/2014)... 29, 2014 Healthpointe is pleased ... Physical Therapy students via Clinical Rotations. ... be shadowing Healthpointe providers and specialists throughout their ... develop clinical experience and learn professional preparation. ... gain insight into several patient care techniques and ...
(Date:8/29/2014)... 2014 Carson Hearing Care has launched ... health care tips to local residents on a consistent ... offer weekly articles from the audiologists at Carson Hearing ... latest advances in hearing restoration research, new tinnitus treatment ... plan to write a new post on the blog ...
(Date:8/29/2014)... US Preventive Services Task Force recommendations for screening and ... may be ameliorated through technological approaches according to a ... published online August 21, 2014 in the Journal ... David Levine, MD, MA, a third year resident in ... colleagues found that compared to usual care, technology-assisted interventions ...
(Date:8/29/2014)... 29, 2014 According to the ... accepting applications next month for medical marijuana, regulators, ... accepting marijuana as a legalized medicine. New marijuana ... be permitted to operate in accordance with local ... best suited to handle legal cannabis. , ...
(Date:8/29/2014)... The microbiology testing sector is one of ... it is also the hugest challenge facing suppliers during ... spread of AIDS – still the world’s key health ... of opportunistic infections (OIs); bioterrorism threat; advancements in technologies ... medicines. Although for certain infections the etiology remains a ...
Breaking Medicine News(10 mins):Health News:Healthpointe is Now Offering Clinical Rotations for Chapman University Physical Therapy Students 2Health News:Fort Worth Hearing Aid Leader, Carson Hearing Care, Creates Expert Blog to Discuss Important Hearing Healthcare Topics 2Health News:Fort Worth Hearing Aid Leader, Carson Hearing Care, Creates Expert Blog to Discuss Important Hearing Healthcare Topics 3Health News:Options for weight loss your primary care doctor might not know about 2Health News:Medical Marijuana Approaches Legalization in Chicago 2Health News:Infectious Disease Testing Universe Examined in New VPG Research Report Available at MarketPublishers.com 2Health News:Infectious Disease Testing Universe Examined in New VPG Research Report Available at MarketPublishers.com 3
... program targeting kids in five-county regionPHILADELPHIA, Jan. 9 ... children have more opportunities and a better life than ... incidence of obesity among children continues to rise, and ... in this country,s history to have a shorter lifespan ...
... today announced that it will develop a custom solution for The Kidney ... presence. , ... Charleston, S.C. (Vocus) January 9, 2009 -- Blackbaud, Inc. ... solution for The Kidney Foundation of Canada that will create a unified ...
... 9 The Society of Gynecologic Oncologists (SGO) will ... 5-8, 2009 at the Henry B. Gonzalez Convention Center ... feature more than 360 scientific presentations in addition to ... focus on emerging science, clinical trials and treatment advances ...
... Robert I. Miller, a 25-year Siemens veteran, ... Industry Group within Siemens IT Solutions and Services, ... http://www.newscom.com/cgi-bin/prnh/20070904/SIEMENSLOGO )In this role, Miller will be ... business plan, including overall go-to-market activities, coordination with ...
... WHITEHALL, Pa., Jan. 9 Protica, Inc., the ... is adding a new brand to its product ... an all-natural version of Profect made with the ... January of 2009. Like Profect, the compact 2.9 ...
... Plans Thousands of Franchisees Nationally With More than 1,800 ... eMed-ID, the world,s first medical identification franchise, announced today ... provides a personal USB device to consumers containing their ... for consumers to document their private medical history on ...
Cached Medicine News:Health News:The Archdiocese of Philadelphia and Independence Blue Cross Team Up to Address Childhood Obesity 2Health News:The Archdiocese of Philadelphia and Independence Blue Cross Team Up to Address Childhood Obesity 3Health News:The Archdiocese of Philadelphia and Independence Blue Cross Team Up to Address Childhood Obesity 4Health News:Blackbaud to Deliver National CRM Database and Bilingual Website for The Kidney Foundation of Canada 2Health News:Blackbaud to Deliver National CRM Database and Bilingual Website for The Kidney Foundation of Canada 3Health News:Blackbaud to Deliver National CRM Database and Bilingual Website for The Kidney Foundation of Canada 4Health News:Society of Gynecologic Oncologists to Host 40th Annual Meeting on Women's Cancer 2Health News:Miller Joins Siemens IT Solutions and Services as V.P. of Healthcare Industry Group 2Health News:Protica Launches All-Natural Protein Beverage, Proasis 2Health News:World's First Medical Identification Franchise Launches at Miami's Franchise Expo South 2Health News:World's First Medical Identification Franchise Launches at Miami's Franchise Expo South 3
... tube extension on the proximal ... helps keep connections away from ... enhancing patient mobility and comfort. ... tubes improve tube access for ...
Fome-Cuf® tubes can breathe with the patient to provide a safe, effective, and low pressure seal throughout the ventilatory cycle....
Aire-Cuf® tracheostomy tubes are ideal for short-term to medium-term ventilator support....
Portex® pediatric tracheostomy tubes offer a choice in both form and fit. , ,The anatomical shape of the tube shaft along with the caudal angle of the 15 mm connector provide comfort and security...
Medicine Products: